Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|23|12|1217-1238

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.12, 2016-05, pp. : 1217-1238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development ofNovel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 7, Iss. 2, 2007-06 ,pp. : 93-97

Bentham Science Publishers

Access to resources Recommend Favorite

Novel dual Src/Abl inhibitors for hematologic and solid malignancies

By Schenone Silvia   Brullo Chiara   Musumeci Francesca   Botta Maurizio  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. : 931-945

Informa Healthcare

Access to resources Recommend Favorite

The Immunoproteasome as a Therapeutic Target for Hematological Malignancies

By  

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 537-548

Bentham Science Publishers

Access to resources Recommend Favorite

IL-22 inhibitors to treat inflammatory disorders such as arthritis

By  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 3, 2003-03 ,pp. : 373-375

Informa Healthcare

Access to resources Recommend Favorite

Selective Inhibitors of Inducible Nitric Oxide Synthase: Potential Agents for the Treatment of Inflammatory Diseases?

By  

Current Topics in Medicinal Chemistry, Vol. 6, Iss. 2, 2006-01 ,pp. : 77-92

Bentham Science Publishers

Access to resources Recommend Favorite